Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Julie Kelly

Research Associate Professor (Clinical Medicine)
BIOMEDICAL SCIENCES INSTITUTE

 kellyja@tcd.ie

 3531896 4438

Research Associate Professor (Trinity Inst. of Neurosciences (TCIN))


Research Projects

 Preclinical Evaluation of a Novel Neurotherapeutic for ALS
 Determining beneficial effects of a new therapeutic compound, JAK4D, in the SOD1 mouse model of Amyotrophic Lateral Sclerosis (ALS)
 Development of a Novel Compound for treating Neurological Disorders.
 Parenteral delivery system for first in class compound with potential therapeutic application in CNS disorders.
 Furthering the development of potent thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE inhibitors - toward a novel therapeutic strategy for CNS disorders.

Page 1 of 3

Memberships

Membership of Professional Institutions, Associations, Societies

Details Date From Date To
The Biochemical Society
American Chemical Society (ACS)
Royal Society of Chemistry (RCS)
International Society for Neurochemistry (ISN)
Sigma Xi
American Association for the Advancement of Science (AAAS)
Kelly JA, Boyle NT, Cole N, Slator GR, Colivicchi MA, Stefanini C, Gobbo OL, Scalabrino GA, Ryan SM, Elamin M, Walsh C, Vajda A, Goggin MM, Campbell M, Mash DC, O'Mara SM, Brayden DJ, Callanan JJ, Tipton KF, Della Corte L, Hunter J, O'Boyle KM, Williams CH, Hardiman O, First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models., Neuropharmacology, 89C, 2015, p193-203 , Journal Article, PUBLISHED  TARA - Full Text  DOI
Campbell M, Kiang AS, Kenna PF, Kerskens C, Blau C, O'Dwyer L, Tivnan A, Kelly JA, Brankin B, Farrar GJ, Humphries P. , RNAi-mediated reversible opening of the blood-brain barrier. , Journal of Gene Medicine, 10, (8), 2008, p930 - 947, Journal Article, PUBLISHED
Hogan N, O'Boyle KM, Hinkle PM, Kelly JA. , A novel TRH analog, Glp-Asn-Pro-d-Tyr-d-TrpNH2, binds to [3H][3-Me-His2]TRH-labelled sites in rat hippocampus and cortex but not pituitary or heterologous cells expressing TRHR1 or TRHR2., Neurosci Lett., 431, (1), 2008, p26-30. , Notes: [PMID: 18069127], Journal Article, PUBLISHED  DOI  URL
Scalabrino GA, Hogan N, O'Boyle KM, Slator GR, Gregg DJ, Fitchett, Discovery of a dual action first-in-class peptide that mimics, Neuropharmacology., 52, (7), 2007, p1472-81 , Notes: [PMID: 17418282], Journal Article, PUBLISHED  DOI  URL
Kelly JA, Scalabrino GA, Slator GR, Cullen AA, Gilmer JF, Lloyd DG, Bennett GW, Bauer K, Tipton KF, Williams CH., Structure-activity studies with high-affinity inhibitors of pyroglutamyl-peptidase II, Biochem J., 389, (Pt 2), 2005, p569 - 576, Notes: [PMID: 15799721], Journal Article, PUBLISHED
Kelly Julie A, Irish Patent Application, Compounds that modulate TRH actions, 2004, PCT/IE2005/000110, Notes: [Application number: Irish Patent Application 2004/0669, PCT/IE2005/000110 filed on 03/10/05. Compounds that modulate TRH actions Inventor: Kelly Julie A Applicant: Trinity College Dublin Priority Date: October 1, 2004], Patent, PUBLISHED
Kelly JA, Slator GR, O'Boyle KM., Pharmacological distinct binding sites in rat brain for [3H]-thyrotropin-releasing hormone (TRH) and [3H][3-methyl-histidine2]TRH, Biochem. Pharmacol., 63, (12), 2002, p2197 - 2206, Notes: [PMID: 12110379], Journal Article, PUBLISHED
Papadopoulos T, Kelly JA, Bauer K., Mutational analysis of the thyrotropin-releasing hormone-degrading ectoenzyme. Similarities and differences with other members of the M1 family of aminopeptidases and thermolysin, Biochemistry, 40, 2001, p9347 - 9355, Notes: [PMID: 11478903], Journal Article, PUBLISHED
Kelly JA, Slator GR, Tipton KF, Williams CH, Bauer K., Kinetic investigation of the specificity of porcine brain thyrotropin-releasing hormone-degrading ectoenzyme for thyrotropin-releasing hormone-like peptides, J. Biol. Chem., 275, (22), 2000, p16746 - 16751, Notes: [PMID: 10748219], Journal Article, PUBLISHED
Kelly Julie A, TRH-like peptide derivatives as inhibitors of the TRH-degrading ectoenzyme, 2000, PCT/IE01/00027; US 0030166944, Notes: [Application number: PCT/IE01/00027; US 0030166944 TRH-like peptide derivatives as inhibitors of the TRH-degrading ectoenzyme Inventor: Kelly Julie A Applicant: Trinity College Dublin Priority Date: February 17, 2000], Patent, PUBLISHED
  

Page 1 of 2

  

Research Interests

Description Of Research Interests

The main focus of Dr Kelly's research relates to understanding the functions of thyrotropin-releasing hormone (TRH) in the central nervous system (CNS) and to enhancing its central therapeutic actions. Based on its central actions, TRH has significant potential in treating a variety of CNS disorders with unmet clinical need, including CNS trauma, spinocerebellar degeneration, epilepsy and depression. Critically, however, the clinical use of TRH and investigation of its CNS functions are hindered due to its rapid degradation. Dr Kelly is currently investigating the properties of novel compounds that may provide a means to reduce TRH degradation and thus may facilitate investigation of TRH actions in an experimental setting and may have potential medical application.